Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy

doi:10.1186/s13020-021-00521-3

	Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy
	Wu,Gaosong 2; Zhao,Jing 2; Zhao,Jing 3; Song,Nixue 1,4; Zheng,Ningning 2; Zeng,Yuanyuan 3; Yao,Tingting 3; Zhang,Jingfang 3; Weng,Jieqiong 3; Yuan,Mengfei 3
刊名	Chinese Medicine
	2021-10-26
卷号	16 期号:1
关键词	Coronary heart disease Syndrome differentiation Traditional Chinese Medicine Proteomics Metabolomics Network pharmacology
DOI	10.1186/s13020-021-00521-3
通讯作者	Shen,Xiaoxu(jhxiaoxushen@163.com) ; Li,Houkai(hk_li@shutcm.edu.cn) ; Zhang,Weidong(wdzhangy@hotmail.com)
英文摘要	AbstractBackgroundTraditional Chinese Medicine (TCM) is distinguished by Syndrome differentiation, which prescribes various formulae for different Syndromes of same disease. This study aims to investigate the underlying mechanism.MethodsUsing a strategy which integrated proteomics, metabolomics study for clinic samples and network pharmacology for six classic TCM formulae, we systemically explored the biological basis of TCM Syndrome differentiation for two typical Syndromes of CHD: Cold Congealing and Qi Stagnation (CCQS), and Qi Stagnation and Blood Stasis (QSBS).ResultsOur study revealed that CHD patients with CCQS Syndrome were characterized with alteration in pantothenate and CoA biosynthesis, while more extensively altered pathways including D-glutamine and D-glutamate metabolism; alanine, aspartate and glutamate metabolism, and glyoxylate and dicarboxylate metabolism, were present in QSBS patients. Furthermore, our results suggested that the down-expressed PON1 and ADIPOQ might be potential biomarkers for CCQS Syndrome, while the down-expressed APOE and APOA1 for QSBS Syndrome in CHD patients. In addition, network pharmacology and integrated analysis indicated possible comorbidity differences between the two Syndromes, that is, CCQS or QSBS Syndrome was strongly linked to diabetes or ischemic stroke, respectively, which is consistent with the complication disparity between the enrolled patients with two different Syndromes. These results confirmed our assumption that the molecules and biological processes regulated by the Syndrome-specific formulae could be associated with dysfunctional objects caused by the Syndrome of the disease.ConclusionThis study provided evidence-based strategy for exploring the biological basis of Syndrome differentiation in TCM, which sheds light on the translation of TCM theory in the practice of precision medicine.
语种	英语
出版者	BioMed Central
WOS记录号	BMC:10.1186/S13020-021-00521-3
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/298326]
专题	中国科学院上海药物研究所
通讯作者	Shen,Xiaoxu; Li,Houkai; Zhang,Weidong
作者单位	1.University of Chinese Academy of Sciences 2.Shanghai University of Traditional Chinese Medicine; Institute of Interdisciplinary Integrative Medicine Research 3.Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine 4.Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research 5.Second Military Medical University; Department of Phytochemistry, School of Pharmacy
推荐引用方式 GB/T 7714	Wu,Gaosong,Zhao,Jing,Zhao,Jing,et al. Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy[J]. Chinese Medicine,2021,16(1).
APA	Wu,Gaosong.,Zhao,Jing.,Zhao,Jing.,Song,Nixue.,Zheng,Ningning.,...&Zhang,Weidong.(2021).Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy.Chinese Medicine,16(1).
MLA	Wu,Gaosong,et al."Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy".Chinese Medicine 16.1(2021).